The current treatment armamentarium for non-small-cell lung cancer (NSCLC) is dominated by biomarker-driven therapies and immune checkpoint inhibitors. In 2020, Opdivo and Yervoy combination regimens and Tecentriq monotherapy gained approval for the first-line treatment of metastatic NSCLC. In addition, the MET and RET inhibitors Tabrecta, Tepmetko, Retevmo, and Gavreto launched for NSCLC harboring MET and RET aberrations. Tagrisso demonstrated a disease-free survival benefit as adjuvant treatment, and its subsequent approval has increased treatment options for EGFR-positive patients with early-stage disease. In this dynamic and rapidly evolving therapeutic landscape, our primary research provides insight into the current use of approved therapies for NSCLC in the United States and uncovers key factors that influence medical oncologists’ prescribing decisions.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 101 U.S. medical oncologists.
Key Drugs Covered:
Keytruda, Opdivo, Tecentriq, Yervoy, Imfinzi, Vizimpro, Alunbrig, Lorviqua, Tafinlar, Mekinist, Tagrisso, Avastin, Tarceva, Xalkori, Alecensa, Iressa, Gilotrif, Tabrecta, Tepmetko, Retevmo, Gavreto